Leucocyte activation markers in clinical practice

Clinical Chemistry and Laboratory Medicine

Volumn 37, Issue 6, 1999, Pages 607-622

  Contreras, José Antonio Viedma ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b Avenida del Doctor Gadea No 1 18F ^*  (Spain)

Author keywords

Cellular mediators; Host defense; Leukocyte activation; Multiple organ dysfunction; Sepsis; Systemic inflammatory response syndrome

Indexed keywords

CD14 ANTIGEN; CYTOKINE; HLA DR ANTIGEN; LIPID; NEOPTERIN; OXYGEN RADICAL; PHOSPHOLIPASE A2; PROCALCITONIN; PROTEINASE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE HEMORRHAGIC PANCREATITIS; HOST RESISTANCE; HUMAN; IMMUNOPATHOLOGY; INFECTION; LEUKOCYTE ACTIVATION; MACROPHAGE; MONOCYTE; MULTIPLE ORGAN FAILURE; NEUTROPHIL; OXIDATIVE STRESS; PHAGOCYTOSIS; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE INJURY;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; LEUKOCYTES; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; NEUTROPHIL ACTIVATION;

EID: 0032845413     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1999.096     Document Type: Review

References (226)

1. Wakefield CH, Carey PD, Foulds S, Monson JRT, Guillou PJ, Polymorphonuclear leukocyte activation. An early marker of postsurgical sepsis response. Arch Surg 1993; 128:390-5.
2. Klava A, Windsor ACJ, Ramsden CW, Guillou PJ. Enhanced polymorphonuclear leukocyte adhesion after surgical injury. Eur J Surg 1997; 167:747-52.
3. Simms HH, D'Amico R. Polymorphonuclear leukocyte dysregulation during the systemic inflammatory response syndrome. Blood 1994; 83:1398-1407.
4. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320:365-76.
5. Jacob HS, Craddock PR, Hammerschmidt DE, Moldow CF. Complement-induced granulocyte activation. An unsuspected mechanism of disease. N Engl J Med 1980; 302:789-94.
6. Fujishima S, Aikawa N. Neutrophil-mediated tissue injury and its modulation. Intens Care Md 1995; 21:277-85.
7. Moore FD, Davis C, Rodrick M, Mannick JA, Fearon DT. Neutrophil activation in thermal injury as assessed by increased expression of complement receptors. N Engl J Med 1986; 314:948-53.
8. Vidarsson G, van de Winkel JGJ. Fc receptor and complement-receptor mediated phagocytosis in host defence. Curr Opin Infect Dis 1998; 11:2712-8.
9. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998; 92:3007-17.
10. Weissmann G, Smolen JE, Korchak HM. Release of inflammatory mediators from stimulated neutrophils. N Engl J Med 1980; 303:27-34.
11. Fantone JC, Ward PA. Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol 1982; 107:397-418.
12. Jochum M, Duswald KH, Neumann S, Witte J, Fritz H, Seemüller U. Proteinases and their inhibitors in inflammation: basic concepts and clinical implication. In: Katununa N, Umezawa V, Holzer H, editors. Proteinase inhibitors, medical and biologial aspects. Heidelberg: Springer-Verlag, 1983:85-9.
13. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJH. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980; 286:264-5.
14. Ford-Hutchinson A, Gresser M, Young R, 5-Lipocygenase. Annu Rev Biochem 1994; 63:383-417.
15. Johnson HM, Torres BA. Leukotrienes: positive signals for regulation of gamma-interferon production. J Immunol 1984; 132:413-6.
16. Venable ME. Platelet activating factor: a phospholipid autacoid with diverse actions. J Lipid Res 1993; 34:691-702.
17. Marcus AJ. Transcellular metabolism of eicosanoids. Prog Hemost Thromb 1986; 8:127-42.
18. Campbell PA. The neutrophil, a professional killer of bacteria, may be controlled by T cells. Clin Exp Immunol 1990; 79:141-3.
19. Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence from an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 1993; 178:2207-11.
20. Nuytinck HKS, Offermans XJMW, Kubat K, Goris JA. Whole-body inflammation in trauma patients. An autopsy study. Arch Surg 1988; 123:1519-24.
21. Collota F, Polentarutti N, Sozzani S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992; 80:2012-20.
22. Glasser L, Fiederlein RL. Functional differentiation of normal human neutrophils. Blood 1987; 69:937-44.
23. Matzner Y. Acquired neutrophil dysfunction and diseases with an inflammatory component. Semin Hematol 1997; 34:291-302.
24. Utoh J, Yamamoto T, Utsunomiya T, Kambara T, Goto H, Miyauchi Y. Effect of surgery on neutrophil functions, superoxide and leukotriene production. Br J Surg 1988; 75:682-5.
25. Duignan JP, Collins PB, Johnson AH, Bouchier-Hayes D. The association of impaired neutrophil chemotaxis with postoperative surgical sepsis. Br J Surg 1986; 73:238-40.
26. Marie C, Muret J, Fitting C, Losser M-R, Payen D, Cavaillon J-M. Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory response syndrome. Blood 1998; 91:3439-46.
27. Simms HH, D'Amico R. Posttraumatic auto-oxidative polymorphonuclear neutrophil receptor injury predicts the development of nosocomial infection. Arch Surg 1997; 132:171-7.
28. de Haas M, Vossebeld PJM, von dem Borne AEGK, Roos D. Fcγ receptors of phagocytes. J Lab Clin Med 1995; 126:330-41.
29. Wakefield CH, Caey PD, Foulds S, Monson JRT, Guillou PJ. Surgery and the release of a neutrophil Fcγ receptor. Am J Surg 1995; 170:277-84.
30. Guillou PJ. Biological variation in the development of sepsis after surgery or trauma. Lancet 1993; 324:217-20.
31. Müller-Kobold AC, Zijlstra JG, Koene HR, de Haas M, Kallenberg CGM, Cohen Tervaert JW. Levels of soluble FcγRIII correlate with disease severity in sepsis. Clin Exp Immunol 1998; 114:220-7.
32. Rothe G, Kellermann W, Valet G. Flow cytometric parameters of neutrophil functions as early indicators of sepsis-or trauma-related pulmonary or cardiovascular organ failure. J Lab Clin Med 1990; 115:52-61.
33. Liras G, Carballo F. An impaired phagocytic function is associated with leukocyte activation in the early stages of severe acute pancreatitis. Gut 1996; 39:39-42.
34. Vowells SJ, Sekhsaria S, Malech HL, Shalit M, Fleisher TA. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J Immunol Methods 1995; 178:89-97.
35. Pacher R, Redl H, Frass M, Petzl DH, Schuster E, Woloszczuk W. Relationship between neopterin and granulocyte elastase plasma levels and the severity of multiple organ failure. Crit Care Med 1989; 17:221-6.
36. Redl H, Schlag G, Bahrami S, Schade U, Ceska M, Stütz P. Plasma neutrophil-activating peptide-1/interleukin-8 and neutrophil elastase in a primate bacteremia model. J Infect Dis 1991; 164:373-88.
37. Nuytinck JKS, Goris JA, REdl H, Schlag G, van Munster PJJ. Posttraumatic complications and inflammatory mediators. Arch Surg 1986; 121:886-90.
38. Gross V, Schölmerich J, Leser H-G, Salm R, Lausen M, Rückauer K, et al. Granulocyte elastase in assessment of severity of acute pancreatitis. Comparison with acute-phase proteins C-reactive protein, 1-antitrypsin, and protease inhibitor α2-macroglobulin. Dig Dis Sci 1990; 35:997-105.
39. Viedma JA; Pérez-Mateo M, Agulló J, Dominguez JE, Carballo F. Inflammatory response in the early prediction of severity in human acute pancreatitis. Gut 1994; 35:822-7.
40. Dominguez-Muñoz JE, Carballo F, García MJ, de Diego JM, Rábago L, Simón MA, et al. Clinical usefulness of polymorphonuclear elastase in predicting the severity of acute pancreatitis: results of a multicentre study. Br J Surg 1991; 78:1230-4.
41. Tsai K, Wang SS, Chen TS, Kong CE, Chang FY, Lee SD, et al. Oxidative stress: an important phenomenon with pathogenetic significance in the progression of acute pancreatitis. Gut 1998; 42:850-5.
42. Dalaman G, Haklar G, Sipahiu A, Ozener C, Akoglu E, Yalcin AS. Early detection of peritonitis in continuous ambulatory peritoneal dyalysis patients by use of chemiluminescence: Evaluation of diagnostic accuracy by receiver-operating characteristic curve analysis. Clin Chem 1998; 44:1680-4.
43. 2 and plasma polymorphonuclear elastase (PMN-E) in different-severity forms of human AP. Pancreas 1998; 17:163-8.
44. Mathru M, Rooney MW, Dries DJ, Hirsch LJ, Barnes L, Tobin MH. Urine hydrogen peroxide during adult respiratory distress syndrome in patients with and without sepsis. Chest 1994; 105:232-6.
45. Roumen RM, Hendriks T, Man BMD, Goris RJ. Serum lipofuscin as a prognostic indicator of adult respiratory distress syndrome and multiple organ failure. Br J Surg 1994; 81:1300-5.
46. 2 propeptide immunoreactivity is released from activated granuloctes. Clin Biochem 1995; 28:71-8.
47. 2 propeptide in acute lung injury. Lancet 1994, 344:1472-3.
48. 2 in inflammatory diseases. Clin Chem 1993; 39:2453-9.
49. Viedma JA, Pérez-Mateo M, Domínguez JE, Carballo F. Role of interleukin-6 in acute pancreatitis. Comparison with C-reative protein and phospholipase A. Gut 1992; 33:1264-7.
50. 2 in serum is an acute phase reactant. Res Comm Chem Pathol Pharmacol 1992; 75:109-15.
51. 2 assay modified for serum analysis. Clin Chem 1993; 39:605-13.
52. 2 against Gram-positive bacteria. J Clin Invest 1999; 103:715-21.
53. 2 in patients with septic shock and trauma. Intensive Care Med 1994; 20:555-61.
54. Hoffmann GE, Schmidt D, Bastian B, Guder WG. Photometric determination of phospholipase A. J Clin Chem Clin Biochem 1986; 24:871-5.
55. 2 in human serum. Clin Chem 1992; 38:1824-9.
56. Schaefer R, Teschner M, Penzel W, Habscheid W, Heidland A, Hoffmann GE: Serum phospholipase A and prognosis in intensive care patients. J Clin Chem Clin Biochem 1990; 28:253-4.
57. 2 and cachectin levels in adult respiratory distress syndrome and multiple-organ failure. Clin Biochem 1992; 25:55-60.
58. 2 in serum in critically ill surgical patients. Crit Care Med 1994; 22:956-9.
59. 2 assays to the assessment of septic shock. Crit Care Med 1990; 18:766-7.
60. Vadas P, Pruzanski W, Stefanski E, Sternby B, Mustard R, Bohnen J, et al. Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse. Crit Care Med 1988; 16:1-7.
61. Anderson BO, Bensard DD, Harken AH. The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure. Surg Gynecol Obstetr 1991; 172:415-24.
62. Henson PM, Barnes PJ, Banks-Schelgel SP. Platelet-activating factor: role in pulmonary injury and dysfunction and blood abnormalities. Am Rev Respir Dis 1992; 145:726-31.
63. Rook G, Balkwill F. Cell-mediated immune reactions. In: Roitt I, Brostoff J, Male D. Immunology. Fifth edition. London: Mosby, 1998:121-35.
64. Christou NV, Mannick JA, West MA, Kasper DL. Lymphocyte-macrophage interactions in the response to surgical infections. Panel discussion-surgical infection society 1986. Arch Surg 1987; 122:239-47.
65. Scott P. IL-12: initiation cytokine for cell-mediated immunity. Science 1993; 260:496-7.
66. Bohn E, Sing A, Zumbihl R, Bielfeldt C, Okamura H, Kurimoto M, et al. IL-18 (IFN-γ-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. J Immunol 1998; 160:299-307.
67. Bradley LM, Dalton DK, Croft M. A direct role for IFN-γ in regulation of Th1 cell development. J Immunol 1996; 157:1350-8.
68. Akiyoshi T, Koba F, Arinaga S, Miyazaki S, Wada T, Tsuji H. Impaired production of interleukin-2 after surgery. Clin Exp Immunol 1985; 59:45-9.
69. Livingston DH, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC. Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg 1988; 123:1309-12.
70. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin-10. J Exp Med 1991; 174:1549-55.
71. Randow F, Syrbe U, Meisel C, Krausch D, Zuckermann H, Platzer C, et al. Mechanism of endotoxin desensitization: involvement of interleukin-10 and transforming growth factor β. J Exp Med 1995; 181:1887-92.
72. Karres I, Kremer J-P, Steckholzer U, Kenney JS, Ertel W. Transforming growth factor inhibits synthesis of cytokines in endotoxin-stimulated human whole blood. Arch Surg 1996; 131:1310-7.
73. Desmedt M, Rottiers P, Dooms H, Fiers W, Grooten J. Macrophages induce cellular immuntiy by activating Th1 cell responses and suppressing Th2 cell responses. J Immunol 1998; 160:5300-8.
74. Guillou PJ. Adjuvant biological response modifiers after major surgery or trauma. Br J Surg 1995; 82:721-3.
75. Klava A, Windsor ACJ, Farmery SM, Woodhouse LF, Reynolds JV, Ramsden CW, et al. Interleukin-10. A role in the development of post-operative immunosuppression. Arch Surg 1997; 132:425-9.
76. Polk HC. Monocyte expression of class II antigens. Br J Surg 1993; 80:138-40.
77. Ditschkowski M, Kreuzfelder E, Regmann V, Ferencik S, Majestschak M, Schmid EN, et al. HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg 1999; 229:246-54.
78. Astiz M, Saha D, Lustbader D, Lin R, Rackow E. Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis. J Lab Clin Med 1996; 128:594-600.
79. Heumann D, Glauser MP, Calandra T. Monocyte deactivation in septic shock. Curr Opin Infect Dis 1998; 11:279-83.
80. Wakefield CH, Carey PD, Foulds S, Monson JRT, Guillou PJ. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg 1993; 80:205-9.
81. Hershman MJ, Cheadle WG, Wellhausen SR, Davidson PF, Polk HC. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg 1990; 77:204-7.
82. Hershman MJ, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC. Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clin Exp Immunol 1989; 77:67-70.
83. Dries DJ. Interferon-γ therapy for infectious complications of injury: a called third strike? Crit Care Med 1998; 26:419-20.
84. Murray HW. Interferon-gamma in infection and immunoparalysis. Intensive Care Med 1996; 22:8455.
85. Kox WJ, Bone RC, Krausch D, Döche W-D, Kox SN, Wauer H, et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Inter Med 1997; 157:389-93.
86. Heinzelmann M, Mercer-Jones M, Cheadle WG, Polk HC. CD14 expression in injured patients correlates with outcome. Ann Surg 1996; 1:91-6.
87. Krüger C, Schütt C, Obertacke U, Joka T, Müller FE, Knöller J, et al. Serum CD14 levels in polytraumatized and severe burned patients. Clin Exp Immunol 1991; 85:297-301.
88. Gebhard F, Rösch M, Helm M, Strecker W, Buttenschön K, Kinzl L, et al. Is the activity of soluble CD14 enhanced following major trauma? Arch Surg 1997; 132:1116-20.
89. De Beaux AC, Fearon KCH. Circulating endotoxin, tumor necrosis factor alpha-1, and their natural antagonists in the pathophysiology of acute pancreatitis. Scand J Gastroenterol 1996; 31:Suppl 219:43-6.
90. Kimura F, Miyazaki M, Suwa T, Sugiura T, Shinoda T, Itoh H, et al. Plasma concentration of cytokine antagonists in patients with infection following liver resection. Br J Surg 1998; 85:1631-5.
91. De Beaux AC, Goldie AS, Ross JA, Carter DC, Fearon KCH. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg 1996; 83:349-53.
92. Van der Poll T, Calvano SE, Kumar A, Braxton CC, Coyle SM, Barbosa K, et al. Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood 1995; 86:2754-9.
93. Calvano SE, Van der Poll T. Coyle SM, Barie PS, Moldawer LL, Lowry SF. Monocyte tumor necrosis factor receptor levels as a predictor of risk in human sepsis. Arch Surg 1996; 131:434-7.
94. Calvano SE, Coyle SM, Barbosa KS, Barie PS, Lowry SF. Multivariate analysis of 9 disease-associated variables for outcome prediction in patients with sepsis. Arch Surg 1998; 133:1347-50.
95. Munoz C, Carlet J, Fitting C, Misset B, Blériot J-P, Cavaillon J-M. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991; 88:1747-54.
96. Ertel W, Kremer J-P, Kenney J. Steeckholzer U, Jarrar D, Trentz O, et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995; 85:1341-7.
97. Faist E, Mewes A, Strasser T, Walz A, Alkan S, Baker C, et al. Alterations of monocyte function following major injury. Arch Surg 1988; 123:287-92.
98. Barry MC, Condron CM, Watson RWG, Redmond HP, El Jack M, Watson RGK, et al. Pre-operative neutrophil and monocyte activation state predicts post-operative neutrophil and monocyte function. Eur J Surg 1997; 163:739-45.
99. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor κ B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 1998; 24:1131-8.
100. McKay CJ, Gallagher G, Brooks B, Imrie CW, Baxter JN. Increased monocyte cytokine production in association with systemic complications in acute pancreatitis. Br J Surg 1996; 83:919-23.
101. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996; 24:163-72.
102. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Inter Med 1996; 125:680-7.
103. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome JAMA 1993; 269:1829-35.
104. Molloy RG, Mannick JA, Rodrick ML. Cytokines, sepsis and immunomodulation. Br J Surg 1993; 80:289-97.
105. Bone RC. Why sepsis trials fall. JAMA 1996; 279:565-6.
106. Beal AL, Cerra FB. Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. JAMA 1994; 271:226-33.
107. Goldie AS, Fearon KCH, Ross JA, Barclay GR, Jackson RE, Grant IS, et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 1995; 274:172-7.
108. Windsor JA, Fearon KCH, Ross JA, Barclay GR, Smyth E, Poxton I, et al. Role of serum endotoxin and antiendotoxin core antibody levels in predicting the development of multiple organ failure in acute pancreatitis. Br J Surg 1993; 80:1042-6.
109. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Müller JM, et al. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996; 22:8474-81.
110. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83:113-8.
111. Van Deuren M, van der Ven-Jongekrijg J, Demacker PNM, Bartelink AKM, van Dalen R, Sauerwein RW, et al. Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 1994; 169:157-61.
112. Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW, Wolff SM, et al. Production of interleukin-1-receptor antagonist during experimental endotoxemia. Lancet 1991; 338:1423-4.
113. Fischer E, Van Zee KJ, Marano MA, Rock CS, Kenney S, Poutsiaka DD, et al. Interleukin-1-receptor antagonist circulates in experimental inflammation and in human disease. Blood 1992; 79:2196-2200.
114. Küster H, Weiss M, Willeitner AE, Detlefsen S, Jeremias I, Zbojan J, et al. Interleukin-1-receptor antagonist and interleukin-6 for early diangosis of neonatal sepsis 2 days before clinical manifestation. Lancet 1998; 352:1271-7.
115. Wanidworanum C, Strober W. Predominant role of tumor necrosis factor-a in human monocyte IL-10 synthesis. J Immunol 1993; 151:6853-61.
116. Donnelly SC, Strieter RM, Reid PT, Kunkel SL, Burdick MD, Mackenzie A, et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1-receptor antagonist in the lung fluid of patients with the adult respiratory distress syndrome. Ann Intern Med 1996; 125:191-6.
117. Kurtzhals JAL, Adabayeri V, Goka BQ, Akanmoru BD, Oliver-Commey J, Nkrumah FK, et al. Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria. Lancet 1998; 351:1768-72.
118. Van Dissel JT, van Langevelde P, Westendorp RGJ, Kwappenberg K, Frölich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998; 351:950-3.
119. Babson AL. The IMMULITE automated immunoassay system. J Clin Immunoassay 1991; 14:83-8.
120. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989; 27:81-141.
121. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 1992; 29:307-41.
122. Faist E, Storck M, Hültner L, Redl H, Eitel W, Walz A, et al. Functional analysis of monocyte activity through synthesis patterns of proinflammatory cytokines and neopterin in patients in surgical intensive care. Surgery 1992; 1112:562-72.
123. Mayersbach P, Augustin R, Schennach H, Schönitzer D, Werner ER, Watcher H, et al. Commercial enzyme linked immunosorbant assay for neopterin detection in blood donations compared with RIA and HPLC. Clin Chem 1994; 40:265-6.
124. Schäfer AJ, Daniel V, Dreikorn K, Opelz G. Assessment of plasma neopterin in clinical kidney transplantation. Transplantation 1986; 41:454-9.
125. Müller TF, Vogl M, Neumann MC, Lange H, Grimm M, Müller MM. Noninvasive monitoring using serum amyloid A and serum neopterin in cardiac transplantation. Clin Chim Acta 1998; 276:63-74.
126. Barak M, Merzbach D, Gruener N. Neopterin measured in serum and tissue culture supernates by a competitive enzyme-linked immunosorbant assay. Clin Chem 1989; 35:1467-71.
127. Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Simultaneous determination of neopterin and creatinine in serum with solid-phase extraction and on-line elution liquid chromatography. Clin Chem 1987; 33:2028-33.
128. Meisner M. PCT, Procalcitonin - a new, innovative infection parameter. Berlin: Brahms-Diagnostica, 1996.
129. Oberhoffer M, Russwurm S, Stonans I, Stonane E, Junker U, Vogelsang H, et al. Human peripheral blood mononuclear cells express mRNA for procalcitonin [abstract]. Br J Anaesth 1998; 80: Suppl 1:155.
130. Braithwaite SS. Procalcitonin - marker or mediator? Crit Care Med 1998; 26:977-8.
131. Nylen ES, Whang KT, Snider RH, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998; 26:1001-6.
132. Gramm H-J, Beier W, Zimmermann J. Qedra N, Hannemann L, Boese-Landgraf J. Procalcitonin (PCT) - a biological marker of the inflammatory response with prognostic properties [abstract]. Clin Intens Care 1995; 6:71.
133. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuan C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341:515-8.
134. Gendrel D, Raymond J, Assicot M, Moulin F, Iniguez J-L, Lebon P. et al. Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis 1997; 24:1240-2.
135. Faist E, Kupper TS, Baker CC, Chaudry IH, Dwyer J, Baue AE. Depression of cellular immunity after injury: its association with posttraumatic complications and its reversal with immunomodulation. Arch Surg 1986; 121:1000-5.
136. Keane RM, Birmingham W, Shatney CM, Winchurch RA, Munster AM. Prediction of sepsis in the multitraumatic patient by assays of lymphocyte responsiveness. Surg Gynecol Obstetr 1983; 156:163-7.
137. Curley PJ, McMahon MJ, Lancaster F, Banks RE, Barclay GR, Shefta J, et al. Reduction in circulation levels of CD4-positive lymphocytes in acute pancreatitis: relationship toendotoxin, interleukin-6 and disease activity. Br J Surg 1993; 80:1312-5.
138. Widdison AL, Cunningham S. Immune function early in acute pancreatitis. Br J Surg 1996; 83:633-6.
139. Schäffer M, Barbul A. Lymphocyte function in wound healing and following injury. Br J Surg 1998; 85:444-460.
140. O'Mahoney JB, Wood JJ, Rodrick ML, Mannick JA, Changes in T lymphocyte subsets following injury. Assessment by flow cytometry and relationship to sepsis. Ann Surg 1985; 202:580-6.
141. O'Riordain DS, Mendez MV, O'Riordain MG, Molloy RG, Holzheimer RG, Collins K, et al. Molecular mechanism of decreased interleukin-2 production after thermal injury. Surgery 1993; 114:407-415.
142. Wood JJ, Rodrick ML, O'Mahoney JB, Palder SB, Saporoschetz I, d'Eon P, et al. Inadequate interleukin-2 production: a fundamental immunological deficiency in patients with major burns. Ann Surg 1984; 200:311-20.
143. O'Riordain DS, Mendez MV, Holzheimer RG, Collins K, Mannick JA, Rodrick ML. Interleukin-2 receptor expression and function following thermal injury. Arch Surg 1995; 130:165-70.
144. Morgan AF, Mendez MV, O'Riordain DS, Holzheimer RG, Mannick JA, Rodrick ML. Altered gene transcription after burn injury results in depressed T-lymphocyte activation. Ann Surg 1994; 220:342-52.
145. Curley P, Nestor M, Collins K. Saporoschetz I, Mendez M, Mannick JA, et al. Decreased interleukin-2 production in murine acute pancreatitis: potential for immunomodulation. Gastroenterology 1996; 110:583-8.
146. Liles WC. Apoptosis - role in infection and inflammation. Curr Opin Infect Dis 1997; 10:165-70.
147. Faist E, Schinkel C, Zimmer S. Update on the mechanisms of immune supression of injury and immune modulation. Word J Surg 1996; 20:454-9.
148. Sugimoto M, Shimaoka M, Hosotsubo K, Tanigami H, Taenaka N, Kiyono H, et al. Up-regulation of Fas ligand (FasL) mRNA expression in peripheral blood mononuclear cells (PBMC) after major surgery. Clin Exp Immunol 1998; 112:120-5.
149. Wood JJ, O'Mahony JB, Rodrick ML, Eaton R, Demling RH, Mannic JA. Abnormalities of antibody production after thermal injury. An association with reduced interleukin-2 production. Arch Surg 1986; 121:108-15.
150. McRitchie DA, Girotti MJ, Rotsein OD, Teodorczyk-Injeyan JA. Impaired antibody production in blunt trauma. Possible role for T cell dysfunction. Arch Surg 1990; 125:91-6.
151. Decker D, Schöndorf M, Bidlingmaier F, Hirner A, von Ruecker AA. Surgical stress induces a shift in the type-1/type-2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody mediated immunity commensurate to the trauma. Surgery 1996; 119:316-25.
152. Di Padova F, di Padova C, Rovagnati P, Tritapepe R. Appearance of spontaneously Ig secreting B cells in human peripheral blood after surgery. Clin Exp Immunol 1986; 65:582-8.
153. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348-57.
154. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145-73.
155. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12:227-57.
156. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-93.
157. O'Sullivan ST, Lederer JA, Morgan AF, Chin DHL, Mannick JA, Rodrick M. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg 1995; 222:482-92.
158. Mack VE, MacCarter MD, Naama HA, Calvano SE, Daly JM. Dominance of T-helper 2-type cytokines after servere injury. Arch Surg 1996; 131:1303-9.
159. Snijdewint FGM, Kalinski P, Wierenga EA, Bos JD, Kapsenberg ML. Prostaglandin E2differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 1993; 150:5321-9.
160. 2 promotes IL-4 induced IGE and IgG synthesis. J Immunol 1990; 145:2644-51.
161. Coffmann R, von der Weid T. Multiple pathways for the initiation of T helper 2 (Th2) responses. J Exp Med 1997; 185:373-5.
162. Choi P, Reiser H. IL-4: role in disease and regulation of production. Clin Exp Immunol 1998; 113:317-9.
163. Trinchieri G. Interleukin-12 and its role in the generation of Th1 cells. Immunol Today 1993; 14:335-7.
164. DiPiro JT, Howdieshell TR, Goddard JK, Callaway DB, Hamilton RG, Mansberger AR. Association of Interleukin-4 plasma levels with traumatic injury and clinical course. Arch Surg 1995; 130:1159-63.
165. O'Suilleabhain C, O'Sullivan ST, Kelly JL, Lederer J, Mannick JA, Rodrick ML. Interleukin-12 treatment restores normal resistance to bacterial challenge after burn injury. Surgery 1996; 120:290-6.
166. Jung T, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993; 159:197-207.
167. Croft M, Carter L, Swain SL, Dutton RW. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994; 180:1715-28.
168. Picker LJ, Singh MK, Zdraveski Z, Treer JR, Waldrop SL, Bergstresser PR, Maino VC. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 1995; 86:1408-19.
169. Jason J, Larned J. Single-cell cytokine profiles in normal humans: comparison of flow cytometric reagents and stimulation protocols. J Immunol Methods 1997; 207:13-22.
170. Zedler S, Bone RC, Baue AE, v. Donnersmarck GH, Faist E. T-cell reactivity and its predictive role in immunosuppression after burns. Crit Care Med 1999; 27:66-72.
171. Chalmers IMH, Janossy G, Contreras M, Navarrete C. Intracellular cytokine profile of cord and adult blood lymphocytes. Blood 1998; 92:11-8.
172. Michie C, Harvey D. Can expression of CD45RO, a T-cell surface molecule, be used to detect congenital infection? Lancet 1994, 343:1259-60.
173. Brüning T, Daiminger A, Endres G. Diagnostic value of CD45RO expression on circulating T lymphocytes of fetuses and newborn infants with pre-, peri- or early post-natal infections. Clin Exp Immunol 1997; 107:306-11.
174. Hodge S, Hodge G, Flower R, Han P. Surface activation markers of T lymphocytes: role in the detection of infection in neonates. Clin Exp Immunol 1998; 113:33-8.
175. Teodorczyk-Injeyan JA, Sparkes BG, Mills GB, Peters WJ, Falk RE. Impairment of T cell activation in burn patients: a possible mechanism of thermal injury-induced immunosuppression. Clin Exp Immunol 1986; 65:570-81.
176. Schlag G, Redl H. Mediators of injury and inflammation. World J Surg 1996; 20:406-10.
177. Larvin M. Circulating mediators in acute pancreatitis as predictors of severity. Scand J Gastroenterol 1996; 31: Suppl 219:16-19.
178. Kollef H, Schuster DP. The acute respiratory distress syndrome. N Engl J Med 1995; 332:27-37.
179. Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung injury: prognostic and pathogenic significance. Am J Respir Crit Care Med 1997; 155:1187-1205.
180. Marini JJ, Evans TW. Acute lung injury. Am J Respir Crit Care Med 1998; 158:675-9.
181. Tate RM, Repine JE. Neutrophils and the adult respiratory distress syndrome. State of the art. Am Rev Respir Dis 1983; 128:552-9.
182. Windsor ACJ, Mullen PG, Fowler AA, Sugerman HJ. Role of the neutrophil in adult respiratory distress syndrome. Br J Surg 1993; 80:10-7.
183. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS, persistent elevation overtime predicts poor outcome. Chest 1995; 108:1303-14.
184. Donelly SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC, et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patients groups. Lancet 1993; 341:643-7.
185. Kiehl MG, Ostermann H, Thomas M, Müller C, Cassens U, Kienast J. Inflammatory mediators in bronchoalveolar lavage fluid and plasma in leukocytopenic patients with septic shock-induced acute respiratory distress syndrome. Crit Care Med 1998; 26:1194-9.
186. Steinberg KP, Milberg JA, Martin TR, Maunder RJ, Cockrill BA, Hudson LD. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med 1994; 150:113-22.
187. Davies MG, Hagen PO. Systemic inflammatory response syndrome. Br J Surg 1997; 84:920-35.
188. Goris RJA, Boekholtz WKF, van Bebber IPTR, Nuytinck JKS, Schillings PHM. Multiple-organ failure and sepsis without bacteria. An experimental model. Arch Surg 1986; 121:897-901.
189. Tobias PS, Mathison JC, Ulevitch RJ. A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis. J Biol Chem 1988; 263:13470-81.
190. Giannoudis PV, Smith RM, Banks RE, Windsor ACJ, Dickson RA, Guillou PJ. Stimulation of inflammatory markers after blunt trauma. Br J Surg 1998; 85:986-90.
191. Rinderknecht H. Fatal pancreatitis, a consequence of excessive leukocyte stimulation? Int J Pancreatol 1988; 3:105-12.
192. Rinderknecht H. Genetic determinants of mortality in acute necrotizing pancreatitis. Int J Pancreatol 1994; 16:11-5.
193. Hack CE, de Groot ER, Felt-Bersma JF, Nuijens JH, Strack van Schijndel RJM, et al. Increased plasma levels of Interleukin-6 in sepsis. Bood 1989; 74:1704-10.
194. Tsaka T, Herkner KR. Polymorphonuclear elastase in neonatal sepsis. Clin Chim Acta 1990; 193:103-12.
195. 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med 1992; 119:159-68.
196. Offner F, Philippé J, Vogelaers D, Colardyn F, Baele G, Baudrihave M, et al. Serum tumor necrosis factor levels in patients with infectious diseases and septic shock. J Lab Clin Med 1990; 116:100-5.
197. Van Zee KJ, de Forge LE, Fischer E, Marano MA, Kenney JS, Remich DG, et al. IL-8 in septic shock, endotoxemia, and after IL-1 administration. J Immunol 1991; 146:3478-82.
198. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-8.
199. Buck C, Bundschu J, Gallati H, Bartmann P, Pohlandt F. Interleukin-6: a sensitive parameter for the early diagnosis of neonatal bacterial infection. Pediatrics 1994; 93:54-8.
200. Messer J, Eyer D, Donato L, Gallati H, Matis J, Simeoni U. Evaluation of interleukin-6 and soluble receptors of tumor necrosis factor for early diagnosis of neonatal infection. J Pedriatr 1996; 129:574-80.
201. Heney D, Wicher JT. Factors affecting the measurement of cytokines in biological fluids: implications for their clinical measurement. Ann Clin Biochem 1995; 32:358-68.
202. Beger HG, Bittner R, Block S, Büchler M. Bacterial contamination of pancreatic necrosis. A prospective clinical study. Gastroenterology 1986; 91:433-8.
203. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg 1998; 175:76-83.
204. Tenner S, Sica G, Hughes M, Noordhoek E, Feng S, Zinner M, et al. Relationship of necrosis to organ failure in severe acute pancreatitis. Gastroenterology 1997; 113:899-903.
205. Isenmann R, Büchler MW. Infection and acute pancreatitis. Br J Surg 1994; 81:1707-8.
206. Neoptolemos P, Raraty M, Finch M, Sutton R. Acute pancreatitis: the substantial human and financial costs. Gut 1998; 42:886-91.
207. Farkas G, Márton J, Mándi Y, Szederkényi E, Balogh Á. Progress in the management and treatment of infected pancreatic necrosis. Scand J Gastroenterol 1998; 33: Suppl 228:31-7.
208. Rau B, Pralle U, Mayer JM, Beger HG. Role of ultrasonographically guided fine-needle aspiration cytology in the diagnosis of infected pancreatic necrosis Br J Surg 1998; 85:179-84.
209. Rau B, Steinbach G, Gansauge F, Mayer JM, Grünert A, Beger HG. The potential of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut 1997; 41:832-40.
210. 2 in patients with infected pancreatic necroses in acute pancreatitis. Pancreas 1998; 17:272-7.
211. Barnes PF, Mistry SD, Cooper CL, Pirmez C, Rea TH, Modlin RL. Compartmentalization of a CD4+ T lymphocyte subpopulation in tuberculous pleuritis. J Immunol 1989; 142:1114-9.
212. San José E, Valdés L, Sarandeses A, Alvarez D, Chomon B. Diagnostic value of adenosine deaminase and lysozyme in tuberculous pleurisy. Clin Chim Acta 1992; 209:73-81.
213. Chiang CS, Chiang CD, Lin JW, Huang PL, Chu JJ. Neopterin, soluble interleukin-2 receptor and adenosine deaminase levels in pleural effusions. Respiration 1994; 61:150-4.
214. Baganha MF, Mota-Pinto A, Pego MA, Marques MA, Rosa MA, Cordeiro AJ. Neopterin in tuberculous and neoplastic pleural fluids. Lung 1992; 170:155-61.
215. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuño-de-Solo B, Estenoz-Alfaro J. Interferon-gamma in 388 immunocompromised and immunocompetent patients for diagnosing pleural tuberculosis. Eur Respir J 1996; 9:2635-9.
216. Söderblom T, Nyberg P, Teppo AM, Klockars M, Riska H, Pettersson T. Pleural fluid interferon-gamma and tumour necrosis factor-alpha in tuberculous and rheumatoid pleurisy. Eur Respir J 1996; 9:1652-5.
217. Shimokata K, Saka H, Murate T, Hasegawa Y, Hasegawa T. Cytokine content in pleural effusion. Comparison between tuberculous and carcinomatous pleurisy. Chest 1991; 99:1103-7.
218. Barnes PF, Fong SJ, Brennan PJ, Twomey PE, Mazunder A, Modin RL. Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol 1990; 145:149-54.
219. Ribera E, Ocaña I, Martínez, Vazquez JM, Rossell M, Espanol T, Ruibal A. High level of interferon gamma in tuberculous pleural effusion. Chest 1988; 93:308-11.
220. Strieter RM, Koch AE, Antony VB, Pick Jr RB, Standiford TJ, Kunkel SL. The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J Lab Clin Med 1994; 123:183-97.
221. Antony VB. Adenosine deaminase isoenzymes and pleural tuberculosis. J Lab Clin Med 1996; 127:326-7.
222. Shibagaki T, Hasegawa Y, Saito H, Yamori S, Shimokata K. Adenosine deamine isozymes in tuberculous pleural effusion. J Lab Clin Med 1996; 127:348-52.
223. Valdés L, San José E, Alvarez D, Valle JM. Adenosine deaminase (ADA) isoenzyme analysis in pleural effusions: diagnostic role, and relevance to the origin of increased ADA in tuberculous pleurisy. Eur Respir J 1996; 9:747-51.
224. Ferrer J. Pleural tuberculosis. Eur Respir J 1997; 10:942-7.
225. Altare F, Durandy A, Lammas D, Emile J-F, Lammhamedi S, Le Deist F, e tal. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998; 280:1432-5.
226. Ribera E, Español T, Martinez-Vazquez JM, Ocaña I, Encabo G. Lymphocyte proliferation and gamma-interferon production after »in vitro« stimulation with PPD. Differences between tuberculous and nontuberculous pleurisy in patients with positive tuberculin skin test. Chest 1990; 997:1281-5.